Verastem Surges on Strong Q2 Data | Business and Finance News

Verastem Oncology is on a roll, posting strong Q2 2026 earnings with $25.1M in net product revenue and securing $75M in new funding—$50M coming soon—to fuel key data readouts and strategic growth. Their commercial star, AVMAPKI FAKZYNJA CO-PACK, is gaining traction as doctors prescribe it more often and patients stay on treatment longer, signaling growing confidence in its early use. In the pipeline, VS-7375—a precision therapy for KRAS G12D-driven cancers—is showing promising preliminary data with strong tolerability, setting the stage for major updates in October and three Phase Three trials. With solid finances and accelerating clinical momentum, Verastem is poised to hit major milestones this year without needing additional capital. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/22f8d8cc3dfa6cfe